Collagen XXIII: A potential biomarker for the detection of primary and recurrent non-small cell lung cancer

Kristin A. Spivey; Jacqueline Banyard; Luisa M. Solis; Ignacio I. Wistuba; Justine A. Barletta; Leena Gandhi; Henry A. Feldman; Scott J. Rodig; Lucian R. Chirieac; Bruce R. Zetter

doi:10.1158/1055-9965.EPI-09-1095

Collagen XXIII: A potential biomarker for the detection of primary and recurrent non-small cell lung cancer

Kristin A. Spivey, Jacqueline Banyard, Luisa M. Solis, Ignacio I. Wistuba, Justine A. Barletta, Leena Gandhi, Henry A. Feldman, Scott J. Rodig, Lucian R. Chirieac, Bruce R. Zetter

Translational Molecular Pathology

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Background: Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer. The purpose of this study was to determine the protein expression of collagen XXIII in tumor tissues from a variety of cancers and to assess the utility of collagen XXIII as a biomarker for non-small cell lung cancer (NSCLC). Methods: A multicancer tissue microarray was used for the immunohistochemical examination of collagen XXIII protein expression in a variety of cancers. Subsequently, collagen XXIII expression was analyzed in three separate cohorts using tissue microarrays with representative tumor and control lung tissues from NSCLC patients. In addition, NSCLC patient urine samples were analyzed for the presence of collagen XXIII through Western blot. Results: Collagen XXIII was present in tissue samples from a variety of cancers. Within lung cancer tissues, collagen XXIII staining was enriched in NSCLC subtypes. Collagen XXIII was present in 294 of 333 (88%) lung adenocarcinomas and 97 of 133 (73%) squamous cell carcinomas. In urine, collagen XXIII was present in 23 of 29 (79%) NSCLC patient samples but only in 15 of 54 (28%) control samples. High collagen XXIII staining intensity correlated with shorter recurrence-free survival in NSCLC patients. Conclusions: We show the capability of collagen XXIII as a tissue and urinary biomarker for NSCLC, in which positivity in tissue or urine significantly correlates with the presence of NSCLC and high staining intensity is a significant recurrence predictor. Impact: Inclusion of collagen XXIII in a tissue- or urine-based cancer biomarker panel could inform NSCLC patient treatment decisions.

Original language	English (US)
Pages (from-to)	1362-1372
Number of pages	11
Journal	Cancer Epidemiology Biomarkers and Prevention
Volume	19
Issue number	5
DOIs	https://doi.org/10.1158/1055-9965.EPI-09-1095
State	Published - May 2010

ASJC Scopus subject areas

Epidemiology
Oncology

MD Anderson CCSG core facilities

Tissue Biospecimen and Pathology Resource

Access to Document

10.1158/1055-9965.EPI-09-1095

Cite this

Spivey, K. A., Banyard, J., Solis, L. M., Wistuba, I. I., Barletta, J. A., Gandhi, L., Feldman, H. A., Rodig, S. J., Chirieac, L. R., & Zetter, B. R. (2010). Collagen XXIII: A potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiology Biomarkers and Prevention, 19(5), 1362-1372. https://doi.org/10.1158/1055-9965.EPI-09-1095

@article{836334b13a3742058f66bbe575d9a586,

title = "Collagen XXIII: A potential biomarker for the detection of primary and recurrent non-small cell lung cancer",

abstract = "Background: Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer. The purpose of this study was to determine the protein expression of collagen XXIII in tumor tissues from a variety of cancers and to assess the utility of collagen XXIII as a biomarker for non-small cell lung cancer (NSCLC). Methods: A multicancer tissue microarray was used for the immunohistochemical examination of collagen XXIII protein expression in a variety of cancers. Subsequently, collagen XXIII expression was analyzed in three separate cohorts using tissue microarrays with representative tumor and control lung tissues from NSCLC patients. In addition, NSCLC patient urine samples were analyzed for the presence of collagen XXIII through Western blot. Results: Collagen XXIII was present in tissue samples from a variety of cancers. Within lung cancer tissues, collagen XXIII staining was enriched in NSCLC subtypes. Collagen XXIII was present in 294 of 333 (88%) lung adenocarcinomas and 97 of 133 (73%) squamous cell carcinomas. In urine, collagen XXIII was present in 23 of 29 (79%) NSCLC patient samples but only in 15 of 54 (28%) control samples. High collagen XXIII staining intensity correlated with shorter recurrence-free survival in NSCLC patients. Conclusions: We show the capability of collagen XXIII as a tissue and urinary biomarker for NSCLC, in which positivity in tissue or urine significantly correlates with the presence of NSCLC and high staining intensity is a significant recurrence predictor. Impact: Inclusion of collagen XXIII in a tissue- or urine-based cancer biomarker panel could inform NSCLC patient treatment decisions.",

author = "Spivey, {Kristin A.} and Jacqueline Banyard and Solis, {Luisa M.} and Wistuba, {Ignacio I.} and Barletta, {Justine A.} and Leena Gandhi and Feldman, {Henry A.} and Rodig, {Scott J.} and Chirieac, {Lucian R.} and Zetter, {Bruce R.}",

year = "2010",

month = may,

doi = "10.1158/1055-9965.EPI-09-1095",

language = "English (US)",

volume = "19",

pages = "1362--1372",

journal = "Cancer Epidemiology Biomarkers and Prevention",

issn = "1055-9965",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

TY - JOUR

T1 - Collagen XXIII

T2 - A potential biomarker for the detection of primary and recurrent non-small cell lung cancer

AU - Spivey, Kristin A.

AU - Banyard, Jacqueline

AU - Solis, Luisa M.

AU - Wistuba, Ignacio I.

AU - Barletta, Justine A.

AU - Gandhi, Leena

AU - Feldman, Henry A.

AU - Rodig, Scott J.

AU - Chirieac, Lucian R.

AU - Zetter, Bruce R.

PY - 2010/5

Y1 - 2010/5

N2 - Background: Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer. The purpose of this study was to determine the protein expression of collagen XXIII in tumor tissues from a variety of cancers and to assess the utility of collagen XXIII as a biomarker for non-small cell lung cancer (NSCLC). Methods: A multicancer tissue microarray was used for the immunohistochemical examination of collagen XXIII protein expression in a variety of cancers. Subsequently, collagen XXIII expression was analyzed in three separate cohorts using tissue microarrays with representative tumor and control lung tissues from NSCLC patients. In addition, NSCLC patient urine samples were analyzed for the presence of collagen XXIII through Western blot. Results: Collagen XXIII was present in tissue samples from a variety of cancers. Within lung cancer tissues, collagen XXIII staining was enriched in NSCLC subtypes. Collagen XXIII was present in 294 of 333 (88%) lung adenocarcinomas and 97 of 133 (73%) squamous cell carcinomas. In urine, collagen XXIII was present in 23 of 29 (79%) NSCLC patient samples but only in 15 of 54 (28%) control samples. High collagen XXIII staining intensity correlated with shorter recurrence-free survival in NSCLC patients. Conclusions: We show the capability of collagen XXIII as a tissue and urinary biomarker for NSCLC, in which positivity in tissue or urine significantly correlates with the presence of NSCLC and high staining intensity is a significant recurrence predictor. Impact: Inclusion of collagen XXIII in a tissue- or urine-based cancer biomarker panel could inform NSCLC patient treatment decisions.

AB - Background: Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer. The purpose of this study was to determine the protein expression of collagen XXIII in tumor tissues from a variety of cancers and to assess the utility of collagen XXIII as a biomarker for non-small cell lung cancer (NSCLC). Methods: A multicancer tissue microarray was used for the immunohistochemical examination of collagen XXIII protein expression in a variety of cancers. Subsequently, collagen XXIII expression was analyzed in three separate cohorts using tissue microarrays with representative tumor and control lung tissues from NSCLC patients. In addition, NSCLC patient urine samples were analyzed for the presence of collagen XXIII through Western blot. Results: Collagen XXIII was present in tissue samples from a variety of cancers. Within lung cancer tissues, collagen XXIII staining was enriched in NSCLC subtypes. Collagen XXIII was present in 294 of 333 (88%) lung adenocarcinomas and 97 of 133 (73%) squamous cell carcinomas. In urine, collagen XXIII was present in 23 of 29 (79%) NSCLC patient samples but only in 15 of 54 (28%) control samples. High collagen XXIII staining intensity correlated with shorter recurrence-free survival in NSCLC patients. Conclusions: We show the capability of collagen XXIII as a tissue and urinary biomarker for NSCLC, in which positivity in tissue or urine significantly correlates with the presence of NSCLC and high staining intensity is a significant recurrence predictor. Impact: Inclusion of collagen XXIII in a tissue- or urine-based cancer biomarker panel could inform NSCLC patient treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=77952018170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952018170&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-09-1095

DO - 10.1158/1055-9965.EPI-09-1095

M3 - Article

C2 - 20447926

AN - SCOPUS:77952018170

SN - 1055-9965

VL - 19

SP - 1362

EP - 1372

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

IS - 5

ER -

Collagen XXIII: A potential biomarker for the detection of primary and recurrent non-small cell lung cancer

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this